CCEL

Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2024 Financial Results

Retrieved on: 
Monday, April 15, 2024
Biotechnology, General Health, Health, Genetics, Stem Cells, Research, CCEL, Engineering, Duke, Trial of the century, Cryo-Cell International

Cryo-Cell International, Inc. (NYSE American LLC: CCEL ) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal first quarter ended February 29, 2024.

Key Points: 
  • Cryo-Cell International, Inc. (NYSE American LLC: CCEL ) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal first quarter ended February 29, 2024.
  • The revenues for the first quarter of fiscal 2024 were $7.85 million compared to $7.82 million for the first quarter of fiscal 2023.
  • The revenues for the first quarter of fiscal 2024 consisted of $7.81 million in processing and storage fee revenue, $3,000 in product revenue and approximately $44,000 in public banking revenue compared to $7.56 million in processing and storage fees, approximately $32,000 in product revenue and approximately $231,000 in public banking revenue for the first quarter of fiscal 2023.
  • For the three months ended February 29, 2024, the Company recorded $503,000 in research, development and related engineering (“R&D”) expenses versus $79,000 for the three months ended February 28, 2023.

Cryo-Cell Announces Plans to Explore Strategic Alternatives and Spin-off Celle Corp. to Maximize Shareholder Value

Retrieved on: 
Monday, March 25, 2024
Genetics, Health, Stem Cells, Other Health, Duke University, Patent, CCEL, Security (finance), Sale, Cryo-Cell International

There is no assurance that such a transaction will take place.

Key Points: 
  • There is no assurance that such a transaction will take place.
  • Celle Corp. was created to hold certain assets of Cryo-Cell not directly associated with the recurring revenue stream from privately banked, umbilical cord blood specimens.
  • The Patent and Technology License Agreement with Duke University has been transferred to Celle Corp. and other assets and liabilities are expected to be transferred in the near future.
  • Further details, once finalized, will be shared in public filings with the Securities and Exchange Commission.

Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2023

Retrieved on: 
Wednesday, February 28, 2024
Biotechnology, Health, Science, Stem Cells, Research, CCEL, Cryo-Cell International

Consolidated revenues for fiscal 2023 were $31.3 million compared to $30.3 million for fiscal 2022.

Key Points: 
  • Consolidated revenues for fiscal 2023 were $31.3 million compared to $30.3 million for fiscal 2022.
  • As of the twelve months ended November 30, 2023, revenue increased 3%, costs of sales decreased 4% and selling, general and administrative expenses increased 10%.
  • These losses were offset by a tax benefit in the amount of $3.8 million for the twelve months ended November 30, 2023.
  • David Portnoy, Chairman of the Board and Co-CEO, commented, “In spite of the large non-cash charges, Cryo-Cell had another solid year in fiscal 2023.

Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, October 12, 2023
Biotechnology, Health, Science, Stem Cells, Research, Investment, CCEL, Engineering, Risk, Duke, Hypoxia (medical), Medium term note, R, NYSE American, Cerebral palsy, CP, Cryo-Cell International, SWAP, Spectrum, Trial of the century, Pharmaceutical industry

Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2023.

Key Points: 
  • Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2023.
  • Consolidated revenues for the third quarter of fiscal 2023 were $7.87 million compared to $7.68 million for the third quarter of fiscal 2022.
  • The revenues for the third quarter of fiscal 2023 consisted of $7.86 million in processing and storage fees, $3,000 in product revenue and $4,000 in public banking revenue compared to $7.52 million in processing and storage fees, $21,000 in product revenue and $138,000 in public banking revenue for the third quarter of fiscal 2022.
  • During the three months ended August 31, 2023, revenue increased 2%, cost of sales decreased 8% and selling, general and administration expenses increased 6%.

Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2023 Financial Results

Retrieved on: 
Friday, July 14, 2023
Health, Stem Cells, Other Health, Other Science, Research, Science, Biotechnology, CCEL, NYSE American, Trial of the century, Cryo-Cell International, Medium term note, SWAP, Risk, Duke, Engineering

Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2023.

Key Points: 
  • Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2023.
  • Consolidated revenues for the second quarter of fiscal 2023 were $7.77 million compared to $7.63 million for the second quarter of fiscal 2022, a 2% increase.
  • The revenues for the second quarter of fiscal 2023 consisted of $7.58 million in processing and storage fee revenue, $164,000 in public banking revenue and $27,000 in product revenue compared to $7.48 million in processing and storage fee revenue, $117,000 in public banking revenue and $36,000 in product revenue for the second quarter of fiscal 2022.
  • During the second quarter of fiscal 2023, the Company entered into an interest rate SWAP agreement to manage exposure to interest rate risk related to its variable debt obligation under its Term Note (as previously disclosed).

Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2023 Financial Results

Retrieved on: 
Friday, April 21, 2023
General Health, Health, Stem Cells, Other Health, CCEL, NYSE American, Cryo-Cell International, Acquisition, Sale

Cryo-Cell International, Inc. (NYSE American LLC: CCEL ) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal first quarter ended February 28, 2023.

Key Points: 
  • Cryo-Cell International, Inc. (NYSE American LLC: CCEL ) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal first quarter ended February 28, 2023.
  • The revenues for the first quarter of fiscal 2023 were $7.82 million compared to $7.26 million for the first quarter of fiscal 2022.
  • The revenues for the first quarter of fiscal 2023 consisted of $7.56 million in processing and storage fee revenue, $32,000 in product revenue and approximately $231,000 in public banking revenue compared to $7.16 million in processing and storage fees, approximately $18,000 in product revenue and approximately $83,000 in public banking revenue for the first quarter of fiscal 2022.
  • The contingent consideration is the current valuation of the potential earnout that Cord:Use Cord Blood Bank, Inc. is entitled to from the Company’s sale of the public cord blood inventory from and after closing of the acquisition of substantially all of Cord:Use’s assets.

Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2022

Retrieved on: 
Tuesday, February 28, 2023
NYSE American, CCEL, Cryo-Cell International, Cryptocurrency

Consolidated revenues for fiscal 2022 were $30.3 million compared to $28.9 million for fiscal 2021.

Key Points: 
  • Consolidated revenues for fiscal 2022 were $30.3 million compared to $28.9 million for fiscal 2021.
  • The Company reported net income of $2.8 million in fiscal 2022 or $0.33 per basic and diluted share, compared to net income of $2.1 million in fiscal 2021 or $0.26 per basic and $0.25 per diluted shares.
  • Net income for the fiscal year ended November 30, 2022 was due to a 5% increase in revenue, a 2% decrease in cost of sales and a 7% increase in selling, general and administrative expenses compared to the prior fiscal year.
  • Also included in net income for the twelve months ended November 30, 2021 was a public bank inventory impairment charge of $1.2 million.

Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2022 Financial Results

Retrieved on: 
Friday, October 14, 2022
Drug Quality and Security Act, Sale, FACT, Accreditation, Person, Parent, CCEL, Patient, Hospital, Income, Licensure, Securities Act of 1933, Baptist Hospital, Partnership, NYSE American, AABB, Company, Cryo-Cell International, IP, Securities Exchange Act of 1934, GLOBE, Terminology, FDA, COVID-19, Ownership, Duke University, Risk, Pharmaceutical industry

OLDSMAR, Fla., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (the Company), the worlds first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2022.

Key Points: 
  • OLDSMAR, Fla., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (the Company), the worlds first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2022.
  • Consolidated revenues for the third quarter of fiscal 2022 were $7.7 million compared to $7.5 million for the third quarter of fiscal 2021.
  • Founded in 1989, Cryo-Cell International, Inc. is the worlds first private cord blood bank.
  • More than 500,000 parents from 87 countries have entrusted Cryo-Cell International with their babys cord blood and cord tissue stem cells.

Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2022 Financial Results

Retrieved on: 
Wednesday, April 13, 2022
Board, COVID-19, Licensure, CCEL, AABB, Hospital, GLOBE, Sale, Risk, Terminology, Drug Quality and Security Act, Patient, OTC, Duke University, Securities Exchange Act of 1934, Ownership, Person, Baptist Hospital, Company, Cryo-Cell International, Parent, Income, IP, Partnership, FDA, Acquisition, Securities Act of 1933, Accreditation, FACT, Pharmaceutical industry

OLDSMAR, Fla., April 13, 2022 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the Company), the worlds first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal first quarter ended February 28, 2022.

Key Points: 
  • OLDSMAR, Fla., April 13, 2022 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the Company), the worlds first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal first quarter ended February 28, 2022.
  • The revenues for the first quarter of fiscal 2022 were $7.26 million compared to $6.86 million for the first quarter of fiscal 2021.
  • Founded in 1989, Cryo-Cell International, Inc. is the worlds first private cord blood bank.
  • More than 500,000 parents from 87 countries have entrusted Cryo-Cell International with their babys cord blood and cord tissue stem cells.

The Esports Combine™ reveals this year's speaking panels

Retrieved on: 
Friday, October 8, 2021
Growth, Program, CCEL, Importance, Personality, University, New World, Student, Business, Telecommunication, Industry, Taiwan eSports League, World League eSport Bundesliga, Gender gap, New Technology Institute, Athlete, Organization, Video game, Management

The combine, which is completely virtual, will feature educational roundtables and industry-leading panel discussions by the brightest minds in the industry.

Key Points: 
  • The combine, which is completely virtual, will feature educational roundtables and industry-leading panel discussions by the brightest minds in the industry.
  • Hundreds of the largest esports scholarships are up for grabs and gamers will be able to tap into the country's best scholarship opportunities.
  • In addition to GYO Score, Harena Data specializes in esports consultation regarding the development and deployment of esports venues, scholastic esports programs, and esports league concepts.
  • GYO Score is an esports and gaming data analytics platform that seeks to support gamers and esports at all levels.